Roger Zelazny

The Changing Land is a Locus Award nominated fantasy novel written by Roger Zelazny, first published in 1981. The novel resolves the storyline from the various Dilvish, the Damned short stories Elements of the story intentionally reflect the work of H. P. Lovecraft and Frank Belknap Long, including the Hounds of …

Eye of Cat is a 1982 science fiction novel written by Roger Zelazny. It was among his five personal favorite novels from his own oeuvre.

Dilvish le Damné est un recueil de nouvelles de fantasy écrit par Roger Zelazny publié en 1982 aux États-Unis et en mars 2011 en France par les éditions Denoël dans la collection Lunes d'encre. Il est composé en version originale de onze nouvelles qui furent préalablement publiées séparément. L'édition française …

Franc-sorcier est un roman de fantasy écrit par l'écrivain américain Roger Zelazny en 1981. Il est le second volume du cycle L'Enfant de nulle part qui en comprend deux, le premier étant L'Enfant tombé de nulle part.

Donnerjack is a science fiction novel begun by American author Roger Zelazny; completed by his companion Jane Lindskold after his death, it was published 1997. The original title of the book was "Donnerjack, of Virtú". Initially, Zelazny intended for it to be the first of an ambitious trilogy, with the two sequels …

Frost & Fire is a 288-page collection of short stories and essays by Roger Zelazny. It was printed in 1989 by William Morrow.

Today We Choose Faces is a 1973 science fiction novel by Roger Zelazny. As originally constructed, Part 1 was an extensive flashback which followed Part 2, but the order of the sections was changed at the request of editor David Hartwell, who felt that the novel worked better in chronological order. Zelazny later …

A Dark Traveling is a science fiction and fantasy novel by Hugo- and Nebula-award winning author, Roger Zelazny. The story uses teleportation as both fantasy and science fiction elements. It is the only novel he wrote for young adults and one of three books without a heroic protagonist.